Patents by Inventor Santiago Viveros SALAZAR

Santiago Viveros SALAZAR has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240294650
    Abstract: The present disclosure is generally directed to antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a MerTK polypeptide, e.g. a mammalian MerTK or human MerTK, and use of such compositions in preventing, reducing risk, or treating a disease or disorder an individual in need thereof.
    Type: Application
    Filed: March 30, 2021
    Publication date: September 5, 2024
    Inventors: Michael KURNELLAS, Santiago Viveros SALAZAR, Marina ROELL, Angie Grace YEE, Seung-Joo LEE, Tina SCHWABE, Maxime CHAPON, William Francis ESTACIO, Arnon ROSENTHAL
  • Publication number: 20240076362
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal antibodies, humanized antibodies and antibody fragments, that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Application
    Filed: May 1, 2023
    Publication date: March 7, 2024
    Inventors: Jeonghoon SUN, Wei-Hsien HO, Muhammad A. ALHAWAGRI, Philip Ling KONG, Herve RHINN, Hua LONG, Karpagam SRINIVASAN, Ananya MITRA, Daniel P. BERMINGHAM, Klaus-Dieter HEGER, Santiago Viveros SALAZAR, Francesca CIGNARELLA, Ilaria TASSI, Tina SCHWABE, Angie Grace YEE, Arnon ROSENTHAL
  • Patent number: 11667699
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal antibodies, humanized antibodies and antibody fragments, that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Grant
    Filed: July 30, 2020
    Date of Patent: June 6, 2023
    Assignee: Alector LLC
    Inventors: Jeonghoon Sun, Wei-Hsien Ho, Muhammad A. Alhawagri, Philip Ling Kong, Herve Rhinn, Hua Long, Karpagam Srinivasan, Ananya Mitra, Daniel P. Bermingham, Klaus-Dieter Heger, Santiago Viveros Salazar, Francesca Cignarella, Ilaria Tassi, Tina Schwabe, Angie Grace Yee, Arnon Rosenthal
  • Publication number: 20230024528
    Abstract: The present disclosure is generally directed to the use of anti-TREM2 antibodies in preventing, reducing risk, or treating disease in an individual in need thereof.
    Type: Application
    Filed: December 4, 2020
    Publication date: January 26, 2023
    Applicant: Alector LLC
    Inventors: Tina SCHWABE, Ilaria TASSI, Arnon ROSENTHAL, Hua LONG, Santiago Viveros SALAZAR
  • Publication number: 20210079074
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal antibodies, humanized antibodies and antibody fragments, that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Application
    Filed: July 30, 2020
    Publication date: March 18, 2021
    Inventors: Jeonghoon SUN, Wei-Hsien HO, Muhammad A. ALHAWAGRI, Philip Ling KONG, Herve RHINN, Hua LONG, Karpagam SRINIVASAN, Ananya MITRA, Daniel P. BERMINGHAM, Klaus-Dieter HEGER, Santiago Viveros SALAZAR, Francesca CIGNARELLA, Ilaria TASSI, Tina SCHWABE, Angie Grace YEE, Arnon ROSENTHAL